IMPLEMENTATION OF EVIDENCE-BASED MEDICINE IN THE DIAGNOSIS AND PREVENTION OF CARDIOVASCULAR DISEASES
Keywords:
Cardiovascular diseases; evidence-based medicine; early diagnosis; disease prevention; clinical guidelines; risk stratificationAbstract
Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, necessitating the application of scientifically validated approaches to improve diagnostic accuracy and preventive effectiveness. This study aims to analyze the implementation of evidence-based medicine in the diagnosis and prevention of cardiovascular diseases, with a focus on integrating high-quality clinical evidence into routine medical practice. The assessment is based on contemporary clinical guidelines, systematic reviews, and large-scale clinical trials evaluating diagnostic tools, risk stratification models, and preventive interventions for cardiovascular pathology. Particular attention is given to the role of evidence-based diagnostic algorithms, biomarker utilization, and non-invasive imaging techniques, as well as lifestyle and pharmacological prevention strategies supported by robust clinical outcomes. The findings indicate that the systematic application of evidence-based medicine enhances early detection of cardiovascular diseases, improves risk assessment, and significantly reduces the incidence of adverse cardiovascular events. The results underscore that embedding evidence-based principles into diagnostic and preventive strategies is essential for optimizing cardiovascular care and reducing the long-term burden of cardiovascular diseases.
References
1.American Heart Association. (2022). Heart disease and stroke statistics—2022 update. Circulation, 145(8), e153–e639. https://doi.org/10.1161/CIR.0000000000001052
2.European Society of Cardiology. (2021). ESC guidelines on cardiovascular disease prevention. European Heart Journal, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484
3.Haynes, R. B., Devereaux, P. J., & Guyatt, G. H. (2002). Physicians’ and patients’ choices in evidence based practice. BMJ, 324(7350), 1350. https://doi.org/10.1136/bmj.324.7350.1350
4.
Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017). Development and validation of QRISK3. BMJ, 357, j2099. https://doi.org/10.1136/bmj.j2099
5.Piepoli, M. F., Hoes, A. W., Agewall, S., et al. (2016). European guidelines on cardiovascular disease prevention. European Heart Journal, 37(29), 2315–2381. https://doi.org/10.1093/eurheartj/ehw106
6.Yusuf, S., Joseph, P., Rangarajan, S., et al. (2020). Modifiable risk factors associated with myocardial infarction. The Lancet, 395(10226), 795–808. https://doi.org/10.1016/S0140-6736(20)30226-9
7.Ташпулатова, Ф. К., Садыков, А. С., & Галиуллин, Т. И. (2017). МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ТУБЕРКУЛЕЗА ЛЕГКИХ И ВИЧ. Фтизиатрия и пульмонология, (2), 136-136.
8.Bekembayeva, G. S., & Tashpulatova, F. K. (2021). PROGNOSIS OF RESISTANT TUBERCULOSIS COURSE AMONG CHILDREN AND TEENAGERS. Новый день в медицине, (1), 48-51.
9.Khomova, N., Tashpulatova, F., & Sultanov, S. (2017). Compliance-is patient adherence to treatment, as well as partnerships between doctor and patient.
10.Ташпулатова, Ф. К., Галиулин, Т. И., & Жумаев, О. А. (2018). АССОЦИАЦИЯ РИСКА РАЗВИТИЯ КАЗЕОЗНОЙ ПНЕВМОНИИ ПРИ ТУБЕРКУЛЕЗЕ ЛЕГКИХ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ. Интернаука, (14-1), 52-53.
11.Вахабов, А. А., & Ташпулатова, Ф. К. (2018). Поражение печени у больных туберкулезом легких при побочных реакциях от противотуберкулезных препаратов. Молодой ученый, (3), 91-93.
